Loading company
TMOThermo Fisher Scientific Inc.$259.4BA+Built from Biodesix, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Biodesix is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$9.95+1.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $101M to $103M for Fiscal year 2026 — up 15.3% on a year earlier
Just reported
From Biodesix's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$24M
+10% y/y
-10% q/q
Guided
—
No guide given
Actual
-$0.75
Guided
—
No guide given
Actual
-$6.1M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade C
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 23 quarters of Biodesix, Inc.’s grade history. The other 21 go back to May 2021.
